Adaptimmune Therapeutics PLC
ADAPY- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001621227
No open-market purchases or sales by Adaptimmune Therapeutics PLC insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:44 PM ET
Revenue flow, FY2024
Where the revenue went in FY2024, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2024: $70.8M (39.8% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 20, 2025 | Mar 6, 2024 | Mar 6, 2023 | Mar 14, 2022 | Feb 25, 2021 |
| Revenue | $178.0M | $60.3M | $27.1M | $6.15M | $3.96M |
| Cost of revenue | $70.0K | – | – | – | – |
| Research and development | $149.1M | $126.5M | $127.7M | $111.1M | $91.6M |
| Selling, general and administrative | $87.3M | $73.5M | $63.4M | $57.3M | $45.8M |
| Operating income | -$68.8M | -$139.7M | -$164.0M | -$162.2M | -$133.4M |
| Income tax | $3.58M | $1.34M | $2.50M | $791.0K | $162.0K |
| Net income | -$70.8M | -$113.9M | -$165.5M | -$158.1M | -$130.1M |
| EPS, basic | $-0.05 | $-0.09 | $-0.17 | $-0.17 | – |
| EPS, diluted | $-0.05 | $-0.09 | $-0.17 | $-0.17 | – |
| Weighted shares, basic | 1.51B | 1.21B | 967.2M | 934.8M | – |
| Weighted shares, diluted | 1.51B | 1.21B | 967.2M | 934.8M | – |
| Margins and growth | |||||
| Operating margin | -38.6% | -231.8% | -604.0% | -2638.6% | -3370.5% |
| Net margin | -39.8% | -188.9% | -609.5% | -2571.0% | -3286.8% |
| Revenue growth, year over year | +195.3% | +122.0% | +341.5% | +55.4% | +252.8% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 20, 2025 | Mar 6, 2024 | Mar 6, 2023 | Mar 14, 2022 | Feb 25, 2021 |
| Cash and equivalents | $91.1M | $144.0M | $108.0M | $149.9M | $56.9M |
| Accounts receivable | $1.45M | $821.0K | $7.43M | $752.0K | $139.0K |
| Inventory | $7.32M | – | – | – | – |
| Total current assets | $188.2M | $207.6M | $255.4M | $415.5M | $398.2M |
| Property, plant and equipment | $31.3M | $50.9M | $53.5M | $30.5M | $27.8M |
| Intangible assets | $3.88M | $330.0K | $442.0K | $1.00M | $1.73M |
| Total assets | $246.0M | $282.6M | $328.9M | $469.5M | $451.1M |
| Accounts payable | $8.69M | $8.13M | $4.75M | $8.11M | $6.39M |
| Total current liabilities | $64.5M | $72.8M | $64.5M | $62.5M | $39.1M |
| Long-term debt | $50.2M | – | – | – | – |
| Total liabilities | $234.1M | $243.1M | $247.0M | $263.6M | $109.9M |
| Shareholders' equity | $11.8M | $39.5M | $81.9M | $206.0M | $341.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 20, 2025 | Mar 6, 2024 | Mar 6, 2023 | Mar 14, 2022 | Feb 25, 2021 |
| Operating cash flow | -$73.2M | -$140.9M | -$141.8M | $10.7M | -$53.6M |
| Capital expenditures | $886.0K | $4.68M | $29.5M | $8.57M | $2.34M |
| Free cash flow | -$74.1M | -$145.6M | -$171.3M | $2.15M | -$55.9M |
| Stock-based compensation | $12.1M | $11.8M | $18.2M | $20.6M | $10.4M |
| Investing cash flow | -$59.0M | $176.5M | $89.1M | $75.8M | -$278.9M |
| Financing cash flow | $78.7M | $880.0K | $12.9M | $3.29M | $340.1M |
| Net change in cash | -$53.8M | $37.4M | -$42.1M | $90.2M | $6.58M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 6.8% | 19.5% | 67.2% | 335.5% | 263.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 11, 2025 | 1.59B | +3.6% | SEC |
| May 9, 2025 | 1.59B | +3.7% | SEC |
| Mar 21, 2025 | 1.54B | +4.2% | SEC |
| Nov 12, 2024 | 1.54B | +12.7% | SEC |
| Aug 8, 2024 | 1.53B | +13.1% | SEC |
| May 13, 2024 | 1.53B | +54.2% | SEC |
| Mar 4, 2024 | 1.48B | +49.3% | SEC |
| Nov 7, 2023 | 1.36B | +38.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.